QJM Advance Access originally published online on August 26, 2005
QJM 2005 98(10):737-743; doi:10.1093/qjmed/hci110
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment of imported malaria in adults: a multicentre study in France
From the Service des Maladies infectieuses et tropicales, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, and 1INFECTIO-SUD Formation et Recherche, Nice, France
Address correspondence to Dr S. Ranque, INSERM U. 399Laboratoire de Parasitologie-Mycologie, Faculté de Médecine, 27 Boulevard Jean Moulin, F-13385 Marseille Cedex 5, France. email: stephane.ranque{at}medecine.univ-mrs.fr
Received 29 September 2004 and in revised form 31 May 2005
Background: Data about anti-malarial drugs prescription practices in Europe and the safety of imported malaria treatments are scanty. In 1999, a French consensus development conference published guidelines for the prevention and treatment of imported P. falciparum malaria. The impact of these guidelines has not been evaluated.
Aim: To investigate the impact of these guidelines on the prescription of anti-malarials, and to evaluate the incidence of acute drug events (ADEs) leading to discontinuation of treatment.
Design: Cross-sectional survey.
Methods: Members of the medical staff in 14 French infectious and tropical disease wards completed a standardized form for each patient treated for imported malaria in 2001. A propensity score matching technique was used to estimate the risk of ADEs leading to discontinuation of the regimen.
Results: In the 474 patients studied, quinine was the first-line anti-malarial most often prescribed. Only 3% of patients received halofantrine. Mefloquine was associated with a RR of 4.9 (95%CI 3.27.4, p<0.00001) risk of discontinuation of treatment due to ADEs.
Discussion: The very limited use of halofantrine indicates that the main practice recommendations of the guidelines have been taken into account. Mefloquine was associated with a substantial risk of discontinuing the treatment because of ADEs. This is a serious limitation for the use of mefloquine in the treatment of out-patients with imported malaria.
*See Acknowledgements for list.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Hatz, J. Soto, H. D. Nothdurft, T. Zoller, T. Weitzel, L. Loutan, F. Bricaire, F. Gay, G.-D. Burchard, K. Andriano, et al. Treatment of Acute Uncomplicated Falciparum Malaria with Artemether-Lumefantrine in Nonimmune Populations: A Safety, Efficacy, and Pharmacokinetic Study Am J Trop Med Hyg, February 1, 2008; 78(2): 241 - 247. [Abstract] [Full Text] [PDF] |
||||
